Moderna shares hit a low after report suggests the FDA plans to tie COVID shots to child deaths

Core Viewpoint - The pharmaceutical sector, particularly companies involved in COVID-19 vaccines, is facing significant stock declines following reports linking vaccines to the deaths of 25 minors, which has raised concerns about vaccine safety and regulatory scrutiny [2][3][5]. Group 1: Stock Performance - Moderna shares dropped 7.4% to their lowest level since March 2020, marking a year-to-date decline of over 44% [3]. - Pfizer's shares fell by 3.9%, while BioNTech and Novavax experienced declines of 7.3% and 3.6%, respectively [3]. - This downturn in pharmaceutical stocks contrasts with the broader market, where the S&P 500 has risen more than 12% this year [4]. Group 2: Regulatory Developments - The FDA is expected to present data regarding the vaccine-related deaths at an upcoming advisory panel meeting, which influences vaccine schedules and insurance coverage [5][6]. - The Vaccine Adverse Event Reporting System (VAERS) data, which is self-reported and unverified, is the basis for the FDA's concerns, although it does not establish causation between the vaccine and deaths [6]. Group 3: Changes in Vaccine Policy - The new administration has made significant changes to the vaccine advisory panel, with Secretary Robert F. Kennedy Jr. replacing all members with individuals who have previously criticized vaccines [9]. - The Advisory Committee on Immunization Practices (ACIP) is scheduled to meet on September 18 and 19 to discuss COVID-19 vaccines and other immunizations [10]. Group 4: Company Responses - Moderna's CEO criticized the recent changes in U.S. vaccine policy as a "step backward," emphasizing the rigorous safety monitoring of their vaccine [11]. - Pfizer highlighted extensive data supporting the safety and effectiveness of its vaccine, noting its administration to over one billion individuals [12].